Lymphatic nodule reactive (supraclavicular, lung and armpits).; 2 years of celiac disease with gluten, lactose and fructose intolerance; Severe pain in stomach (epigastric); Migraines; pain in the joints; rectal bleeding; petechiae in the mouth,; chronic swelling; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 33-year-old female patient received bnt162b2 (BNT162B2), on 29Dec2020 as dose 1, single (Lot number: EK5730) at the age of 33 years intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: COELIAC DISEASE (disability) with onset Jan2021, outcome "not recovered", described as "2 years of celiac disease with gluten, lactose and fructose intolerance"; LYMPHADENOPATHY (disability) with onset Jan2021, outcome "not recovered", described as "Lymphatic nodule reactive (supraclavicular, lung and armpits)."; MIGRAINE (disability) with onset Jan2021, outcome "not recovered", described as "Migraines"; ABDOMINAL PAIN UPPER (disability) with onset Jan2021, outcome "not recovered", described as "Severe pain in stomach (epigastric)"; SWELLING (disability) with onset Jan2021, outcome "not recovered", described as "chronic swelling"; ARTHRALGIA (disability) with onset Jan2021, outcome "not recovered", described as "pain in the joints"; MOUTH HAEMORRHAGE (disability) with onset Jan2021, outcome "not recovered", described as "petechiae in the mouth,"; RECTAL HAEMORRHAGE (disability) with onset Jan2021, outcome "not recovered", described as "rectal bleeding". The events "lymphatic nodule reactive (supraclavicular, lung and armpits).", "2 years of celiac disease with gluten, lactose and fructose intolerance", "severe pain in stomach (epigastric)", "migraines", "pain in the joints", "rectal bleeding", "petechiae in the mouth," and "chronic swelling" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 antibody test: (Apr2020) Negative, notes: Nasal Swab; Test: (unspecified date) Unknown results. Therapeutic measures were taken as a result of lymphadenopathy, coeliac disease, abdominal pain upper, migraine, arthralgia, rectal haemorrhage, mouth haemorrhage, swelling. Clinical course: Lymphatic nodule reactive (supraclavicular, lung and armpits). Nodules are still present. Severe pain in stomach (epigastric). Migraines, pain in the joints, rectal bleeding, petechiae in the mouth, chronic swelling. The after 2 years of celiac disease with gluten, lactose and fructose intolerance. Currently rule out for Hodgkin's lymphoma. The symptoms started mild with the first doses and in the second they were intensified until today. The patient had never gotten COVID (the disease). Allergies included gluten, lactose, and fructose; these intolerances were developed after the Covid Vaccine. Treatment of adverse events included Test/medication IV and oral.  According to the patient, the adverse events resulted in disability of permanent damage.; Sender's Comments: Based on plausible temporal association and known safety profile a contributory  role of BNT162b2 to the reported lymphadenopathy and arthralgia is possible.  The reported Coeliac disease, migraine, abdominal pain upper, mouth  hemorrhage, and rectal hemorrhage are intercurrent conditions and are unrelated to  BNT162b2.  Case will be reassessed if additional information is received.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.,Linked Report(s) : PR-PFIZER INC-202300366216 same reporter/patient different dose number;